Supplemental Online Content

Mayer K, Hein-Rothweiler R, Schüpke S, et al. Efficacy and safety of revacept, a novel lesion-directed competitive antagonist to platelet glycoprotein vi, in patients undergoing elective percutaneous coronary intervention for stable ischemic heart disease: the randomized, double-blind, placebo-controlled ISAR-PLASTER phase 2 trial. *JAMA Cardiol*. Published online March 31, 2021. doi:10.1001/jamacardio.2021.0475

This supplemental material has been provided by the authors to give readers additional information about their work.

1. Committees and Investigators

Steering Committee

Adnan Kastrati (Chair)
Klinik für Herz- und Kreislauferkrankungen
Deutsches Herzzentrum München
Technical University of Munich
Lazarettstr. 36, 80636 Munich, Germany

Steffen Massberg
Medizinische Klinik und Poliklinik I
Klinikum der Universität München
Marchioninistr. 15, 81377 Munich, Germany

Karl-Ludwig Laugwitz
1. Medizinische Klinik und Poliklinik
Klinikum rechts der Isar,
Technical University of Munich
Ismaninger Str. 22, 81675 Munich, Germany

Stefanie Schüpke
Klinik für Herz- und Kreislauferkrankungen
Deutsches Herzzentrum München
Technical University of Munich
Lazarettstr. 36, 80636 Munich, Germany

Dirk Sibbing
Privatklinik Lauterbacher Mühle am Ostersee, Iffeldorf and
Medizinische Klinik und Poliklinik I
Klinikum der Universität München
Marchioninistr. 15, 81377 Munich, Germany

Andreas Zeiher
Universitätsklinikum Frankfurt am Main
Medizinische Klinik III, Kardiologie/Angiologie
Theodor-Stern-Kai 7, 60590 Frankfurt/Main, Germany

Data Safety Monitoring Board

Marco Valgimigli (Chair)
Inselspital, Universitätsspital Bern
Universitätsklinik für Kardiologie
Schweizer Herz- und Gefässzentrum Bern
Freiburgstr. 18
3010 Bern, Switzerland

Peter Jüni
Applied Health Research Centre (AHRC)
Li Ka Shing Knowledge Institute of St. Michael´s Hospital

30 Bond St, Toronto, M5B 1W8, Canada

Michael Maeng
Aarhus University Hospital, Department of Cardiology
Palle Juul-Jensens Boulevard 99, 8200 Aarhus N, Denmark

Event Adjudication Committee

Julia Ellert (Chair)
Odense University Hospital
Department of Cardiology
J. B. Winsløws Vej 4
5000 Odense C, Denmark

Fadil Ademaj
Klinikum Nürnberg Süd, Klinik für Innere Medizin 8
Breslauer Str. 201
90471 Nürnberg, Germany

Georg Marcus Fröhlich
HerzClinic Luzern AG
St. Anna-Str. 32
6006 Luzern, Switzerland

Participating Centers and Investigators

Klinik für Herz- und Kreislauferkrankungen, Deutsches Herzzentrum München

Adnan Kastrati (PI), Katharina Mayer (Deputy PI), Jens Wiebe (Deputy PI, FEB/2020)

Investigators: Sebastian Kufner, Tanja Morath, Erion Xhepa

Study Nurses: Tatjana Bruch, Anna Dietrich, Bettina Harrer, Monika Neumeyer

Medizinische Klinik und Poliklinik I (Campus Großhadern and Campus Innenstadt), Klinik der Universität München

Ralph Hein-Rothweiler (PI, JAN/2019), Dirk Sibbing (PI, NOV/2017-JAN/2019), Lisa Gross (Deputy PI - NOV/2017-APR/2019), Danny Kupka (Deputy PI)

Investigators: Stefanie Bieber, Johannes Brado, Simon Deseive, Sarah Gschwendtner, Stefan Kääb, Kathrin Krieg, Anja Loew, Martin Orban, Tobias Petzold, Konstantin Stark, Julius Steffen, Anna Katharina Strüven, Raffael Thaler

Study Nurses: Gabriele Baur, Monika Baylacher, Julia Dominguez-Escobar, Karin Hohenleitner-Lührßen, Janina Neubarth-Mayer, Kseniia Schmidt, Janine Vogt

1. Medizinische Klinik, Klinikum rechts der Isar, München,

Karl-Ludwig Laugwitz (PI), Rainer Okrojek (Deputy PI)

Investigators: Isabell Bernlochner, Christian Bradaric, Ralf Dirschinger, Michael Domasch, Tareg Ibrahim, Christian Kupatt, Mark Lachmann, Jakob Ledwoch, Daniel Sinnecker, Tristan Tschaikowsky

Study Nurses: Christine Berke, Heike Fengler, Sabrina Doering, Dagmar Reitberger, Victoria Zillmann

Medizinische Klinik III - Kardiologie und Angiologie, Eberhard Karls University of Tübingen

Oliver Borst (PI), Tobias Geisler (Deputy PI), Dominik Rath (Deputy PI)

Investigators: Michael Droppa

Study Nurses: Miriam Ayed-Walz, Stefanie Herholz, Martina Heusel, Timea Keller, Diana Lombardi

Department of Cardiology, University Medical Center Mainz

Tommaso Gori (PI), Thomas Münzel (Deputy PI)

Investigators: Zisis Dimitriadis, Sebastian Hollmann, Dudu Kutlu, Anadol Renzi, Bettina Ruff

Study Nurses: Julia Gadinger, Gabriele Gebel, Saskia Goetze, Melanie Hochmuth, Sarah Rohleder, Keslin Schulz, Ilka Walther, Susanne Wüst

Medizinische Klinik für Kardiologie, Charité - Universitätsmedizin Berlin Campus Benjamin Franklin

David Manuel Leistner (PI), Arash Haghikia (Deputy PI)

Investigators: Anne-Sophie Schatz, Denitsa Meteva

Study Nurses: Sevilay Güler, Katja Hubert, Julia Leibiger, Derya Oezcelik, Jasmin Radenkovic, Ines Redlich

Charité - Universitätsmedizin Berlin Campus Virchow

Tobias Trippel (PI), Frank Edelmann (Deputy PI)

Investigators: Felix Bähr, Maximilian Krisper, Johannes Petutschnigg, Cristina Rozados da Conceicao, Leonard Schleußner, Veronika Zach

Study Nurses: Jens Brestrich, Svenja Broschag, Haley Hartmann, Bianca Papke, Angel Phuti, Jasmin Radenkovic, Sophia Strempel

Medizinische Klinik III, Universitätsklinikum Frankfurt am Main

Mariuca Vasa-Nicotera (PI), Andreas Zeiher (Deputy PI)

Investigators: Birgit Aßmus, Eleni Giokoglu, Stephan Fichtlscherer, Philipp Seppelt, Matthias Trumm, Helge Weiler

Study Nurses: Mine Bilge, Margret Müller-Ardogan, Bahar Sabanci, Menza Tekeste, Andrea Wolf, Evelin Wunderlich

2. Coordinating ISAResearch Center

Deutsches Herzzentrum München, Munich:

Adnan Kastrati (Chairman), Stefanie Schüpke (Medical Supervisor)

Project Management:

Marion Janisch, Barbara v. Merzljak, Sonja Siepe

Study Coordination/Study Assistant:

Julia Müller, Anke Wasmund

Data Management:

Eva Grünzinger, Oliver Krueger, Anja Münnich

SAE Management:

Marion Janisch, Silvia Müller, Traian Popescu, Franziska Prömm, Stefanie Schüpke

Monitoring

Andrea Mecklenburg, Silvia Müller, Benedikt Schwartz

3. Statistics

Alexander Hapfelmeier
Institute of Medical Informatics, Statistics and Epidemiology and Institute of General Practice and Health Services Research, School of Medicine, Technical University of Munich, Germany
Ismaninger Str. 22, 81675 Munich, Germany

Kurt Ulm
Klinikum rechts der Isar
Technical University of Munich, Institute of Medical Informatics, Statistics and Epidemiology
Ismaninger Str. 22, 81675 Munich, Germany

4. eTables and eFigure

eTable 1. Angiographic and Interventional Characteristics

Characteristic	**Revacept 160 mg (n = 193)**	**Revacept 80 mg (n = 164)**	**Placebo (n = 160)**
Target vessel, No. (%)			
Left main coronary artery	12 (6.2)	11 (6.7)	8 (5.0)
Left anterior descending coronary artery	90 (46.6)	54 (32.9)	67 (41.9)
Left circumflex coronary artery	43 (22.3)	40 (24.4)	48 (30.0)
Right coronary artery	48 (24.9)	56 (34.1)	37 (23.1)
Bypass graft	0 (0.0)	3 (1.8)	0 (0.0)
Complex lesion (type B2/C), No. (%)	132 (68.4)	105 (64.0)	105 (65.6)
Chronic total occlusion, No. (%)	11 (5.7)	9 (5.5)	9 (5.6)
TIMI flow grade before the intervention, No. (%)			
0	6 (3.1)	4 (2.4)	7 (4.4)
1	2 (1.0)	6 (3.7)	3 (1.9)
2	11 (5.7)	4 (2.4)	5 (3.1)
3	174 (90.2)	150 (91.5)	144 (90.0)
Type of intervention, No. (%)			
Drug eluting stent	184 (95.3)	152 (92.7)	143 (89.4)
Drug eluting balloon	5 (2.6)	7 (4.3)	11 (6.9)
PTCA only	6 (3.1)	12 (7.3)	14 (8.8)
Total stented length, median (IQR), mm[a]	23.0 (18.0, 33.8)	23.0 (18.0, 33.0)	23.0 (18.0, 29.0)
Maximum stent diameter, median (IQR), mm[a]	3.0 (3.0, 3.5)	3.5 (3.0, 3.5)	3.0 (2.8, 3.5)
Maximum balloon diameter, median (IQR), mm[b]	3.5 (3.0, 3.5)	3.5 (3.0, 3.5)	3.0 (2.5, 3.5)
Maximum balloon pressure, median (IQR), atm[c]	15.0 (12.5, 18.0)	14.0 (12.0, 17.5)	14.0 (12.0, 16.0)

TIMI flow grade after the intervention, No. (%)			
0	2 (1.0)	2 (1.2)	0 (0.0)
1	0 (0.0)	1 (0.6)	3 (1.9)
2	0 (0.0)	0 (0.0)	0 (0.0)
3	191 (99.0)	161 (98.2)	156 (97.5)

There were no significant between-group differences in procedural characteristics. PCI, percutaneous coronary intervention; PTCA, percutaneous transluminal coronary angioplasty; TIMI, Thrombolysis in Myocardial Infarction.

[a] Total stent length and maximal stent diameter refer only to lesions treated with stent(s).
[b] Maximum balloon diameter not available in 6 patients (2 in the Revacept 160 mg group, 3 in the Revacept 80 mg group and 1 in the Placebo group).
[c] Maximum balloon pressure not available in 8 patients (2 in the Revacept 160 mg group, 5 in the Revacept 80 mg group and 1 in the Placebo group).

eTable 2. Concomitant Medication

Characteristic	Revacept 160 mg (n = 120)	Revacept 80 mg (n = 121)	Placebo (n = 93)
Drug therapy at Baseline, No. (%)			
Aspirin	111 (92.5)	110 (90.9)	83 (89.2)
Clopidogrel	63 (52.5)	58 (47.9)	58 (62.4)
Statin	107 (89.2)	107 (88.4)	86 (92.5)
Betablocker	63 (52.2)	65 (53.7)	50 (53.8)
ACE inhibitor/ARB	88 (73.3)	95 (78.5)	72 (77.4)
Periprocedural antithrombotic medication			
No study drug, No. (%)[a]	0 (0.0)	2 (1.7)	0 (0.0)
Aspirin loading, No. (%)[b]	85 (70.8)	85 (70.2)	69 (74.2)
Aspirin loading dose, median (IQR), mg[c]	500 (500, 500)	500 (500, 500)	500 (500, 500)
Clopidogrel loading, No. (%)[b]	99 (82.5)	101 (83.5)	74 (79.6)
Clopidogrel loading dose, median (IQR), mg[c]	600 (600, 600)	600 (600, 600)	600 (600, 600)
Unfractionated heparin, No. (%)	120 (100)	121 (100)	93 (100)
Unfractionated heparin total dose, median (IQR), IU	7000 (5000,8000)	7000 (6000,8500)	7000 (6000,8000)
Drug Therapy at Discharge, No. (%)			
Aspirin	119 (99.2)	120 (99.2)	93 (100)
Clopidogrel[d]	120 (100)	120 (99.2)	93 (100)
Statin	117 (97.5)	116 (95.9)	91 (97.8)
Betablocker	77 (64.2)	73 (60.3)	54 (58.1)
ACE inhibitor/ARB	94 (78.3)	102 (84.3)	80 (86.0)

There were no significant between-group differences in concomitant medication.

ACE, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker heparin.

[a] Study medication was not administered in 2 patients in the Revacept 80 mg group (due to concerns with the quality of study drug preparation in 1 patient; due to changed treatment strategy to aorto-coronary bypass surgery in 1 patient).
[b] Aspirin loading was administered immediately prior to and clopidogrel loading on an average of 3.7 hours prior to percutaneous coronary intervention. Patients who did not receive clopidogrel loading were on chronic antiplatelet therapy on admission.
[c] Aspirin and clopidogrel loading doses are shown only for those patients who obtained the respective loading.
[d] Prasugrel was administered at discharge in 1 patient in the Revacept 80 mg group.

eTable 3. Efficacy Endpoints at 30 Days

Characteristic	Revacept 160 mg (n = 120)	Revacept 80 mg (n = 121)	Placebo (n = 93)	P value
All-cause mortality, No. (%)	0	1 (0.8)	0	
Myocardial infarction, No. (%)	3 (2.5)	3 (2.5)	2 (2.2)	
Type 3	0	1	0	
Type 4a	3	1	2	
Type 5	0	1	0	
Definite stent thrombosis, No.	0	0	0	
Urgent coronary revascularization, No. (%)	0	2 (1.7)	0	
Stroke, No.	0	0	0	
Major adverse cardiovascular events, No. (%)[a]	3 (2.5)	4 (3.3)	2 (2.2)	0.91

[a] Major adverse cardiovascular events include death, myocardial infarction, stroke or urgent coronary revascularization.

eTable 4. Laboratory Parameters at 48h

Characteristic	Revacept 160 mg (n = 120)	Revacept 80 mg (n = 119)	Placebo (n = 93)	P value
Biochemistry				
ALAT/SGPT, median (IQR), U/L[a]	21.8 (16.1, 32.5)	22.0 (16.1, 29.5)	21.9 (18.2, 27.5)	0.90
Alkaline phosphatase, median (IQR), U/L[b]	70.6 (62.0, 85.8)	66.9 (53.5, 80.5)	67.0 (58.0, 78.0)	0.07
ASAT/SGOT, median (IQR), U/L[c]	24.2 (19.6, 31.4)	23.1 (19.0, 27.5)	23.5 (19.0, 27.6)	0.40
Blood urea, median (IQR), mg/dL[d]	32.1 (26.3, 40.7)	31.6 (24.9, 38.6)	31.5 (27.9, 35.5)	0.47
Creatine kinase, median (IQR), U/L[e]	97.0 (66.5, 141.0)	89.0 (63.2, 115.8)	91.0 (62.5, 133.5)	0.44
Creatine kinase-myocardial band, median (IQR), U/L[f]	13.8 (11.1, 16.1)	13.8 (10.7, 17.1)	13.6 (11.2, 16.5)	0.99
Gamma-GT, median (IQR), U/L[g]	26.0 (19.9, 46.8)	31.50(21.7, 49.4)	26.8 (19.0, 39.0)	0.16
Creatinine, median (IQR), mg/dL[h]	1.0 (0.9, 1.1)	1.0 (0.9, 1.1)	0.9 (0.8, 1.1)	0.07
Lactate dehydrogenase, median (IQR), U/L[i]	173.0 (150.0, 205.0)	174.0 (150.0, 198.2)	165.0 (149.0, 187.0)	0.46
Glucose, median (IQR), mg/dL[j]	114.0 (99.0, 148.0)	117.0 (103.0, 145.0)	109.0 (99.0, 137.5)	0.17
Sodium, median (IQR), mmol/L[k]	140 (139.0, 141.0)	140 (138.5, 141.0)	140.0 (139.0, 141.0)	0.24
Potassium, median (IQR), mmol/L[l]	4.2 (3.9, 4.4)	4.1 (4.0, 4.3)	4.1 (3.9, 4.4)	0.75
Total bilirubin, median (IQR), mg/dL[m]	0.6 (0.5, 0.9)	0.6 (0.4, 0.9)	0.6 (0.5, 0.8)	0.99
Uric acid, median (IQR), mg/dL[n]	5.5 (4.6, 6.6)	5.4 (4.8, 6.5)	5.5 (4.9, 6.4)	0.99
C-reactive protein, median (IQR), mg/dL[o]	3.0 (1.4, 7.3)	3.6 (1.8, 6.7)	4.4 (1.7, 8.0)	0.38
Hematology				
Hemoglobin, median (IQR), g/dL[p]	13.7 (12.6, 14.8)	14.0 (12.8, 15.4)	13.9 (13.3, 14.8)	0.51
Platelet count, median (IQR), 10^9/L[q]	220.0 (181.5, 244.5)	212.0 (181.0, 245.0)	214.0 (180.8, 245.0)	0.97
Red blood cell count, median (IQR), 10^{12}/L[r]	4.5 (4.2, 4.9)	4.6 (4.1, 5.0)	4.6 (4.4, 4.9)	0.60
White blood cell count, median (IQR), 10^9/L[s]	6.9 (5.8, 8.6)	7.0 (5.7, 8.9)	7.1 (6.0, 8.0)	0.99

Differential Blood Count, median (IQR), %				
Neutrophils[t]	63.0 (59.0, 68.0)	61.0 (57.0, 66.0)	63.0 (58.0, 66.0)	0.27
Lymphocytes[u]	25.0 (20.0, 31.0)	24.9 (21.0, 31.0)	25.0 (21.0, 30.0)	0.97
Eosinophils[v]	2.1 (1.9, 3.6)	3.0 (2.0, 4.0)	2.1 (2.0, 4.0)	0.25
Basophils[w]	1.0 (0.7, 1.0)	1.0 (0.5, 1.0)	1.0 (0.2, 1.0)	0.436
Monocytes[x]	8.0 (7.0, 10.0)	9.0 (8.0, 11.0)	9.0 (7.0, 11.0)	0.04
Coagulation				
Activated partial thromboplastin time , median (IQR), sec[y]	27.0 (25.0, 29.1)	27.4 (25.0, 30.0)	27.6 (25.0, 29.8)	0.73
Quick, median (IQR), %[z]	109.0 (100.2, 116.8)	107.0 (100.0, 115.0)	108.0 (97.2, 114.0)	0.37
International normalized ratio, median (IQR)[aa]	1.0 (0.9, 1.0)	1.0 (0.9, 1.0)	1.0 (0.9, 1.0)	0.19

Data are shown for the modified intention-to-treat population.

ALAT/SGPT, alanine aminotransferase/ serum glutamate-pyruvate transaminase; ASAT/SGOT, aspartate aminotransferase/ serum glutamic-oxaloacetic transaminase; gamma-GT, gamma-glutamyl transferase**.**

[a] ALAT/SGPT not available in 4 patients (1 in the Revacept 160 mg group and 3 in the Placebo group).

[b] Alkaline phosphatase not available in 7 patients (2 in the Revacept 160 mg group, 1 in the Revacept 80 mg group and 4 in the Placebo group).

[c] ASAT/SGOT not available in 3 patients (1 in the Revacept 160 mg group and 2 in the Placebo group).

[d] Blood urea not available in 2 patients (1 in the Revacept 160 mg group and 1 in the Placebo group).

[e] Creatine kinase not available in 4 patients (1 in the Revacept 160 mg group, 1 in the Revacept 80 mg group and 2 in the Placebo group).

[f] Creatine kinase-myocardial band not available in 123 patients (41 in the Revacept 160 mg group, 47 in the Revacept 80 mg group and 35 in the Placebo group).

[g] Gamma-GT not available in 3 patients (1 in the Revacept 160 mg group and 2 in the Placebo group).

[h] Creatinine not available in 2 patients (1 in the Revacept 160 mg group and 1 in the Placebo group).

[i] Lactate dehydrogenase not available in 10 patients (3 in the Revacept 160 mg group, 3 in the Revacept 80 mg group and 4 in the Placebo group).

[j] Glucose not available in 6 patients (2 in the Revacept 160 mg group, 2 in the Revacept 80 mg group and 2 in the Placebo group).

[k] Sodium not available in 2 patients (1 in the Revacept 160 mg group and 1 in the Placebo group).

[l] Potassium not available in 2 patients (1 in the Revacept 160 mg group and 1 in the Placebo group).

[m] Total bilirubin not available in 5 patients (1 in the Revacept 160 mg group, 1 in the Revacept 80 mg group and 3 in the Placebo group).
[n] Uric acid not available in 5 patients (2 in the Revacept 160 mg group, 1 in the Revacept 80 mg group and 2 in the Placebo group).
[o] C-reactive protein not available in 3 patients (1 in the Revacept 160 mg group, 1 in the Revacept 80 mg group and 1 in the Placebo group).
[p] Hemoglobin not available in 2 patients (1 in the Revacept 160 mg group and 1 in the Placebo group).
[q] Platelet count not available in 2 patients (1 in the Revacept 160 mg group and 1 in the Placebo group).
[r] Red blood cell count not available in 2 patients (1 in the Revacept 160 mg group and 1 in the Placebo group).
[s] White blood cell count not available in 2 patients (1 in the Revacept 160 mg group and 1 in the Placebo group).
[t] Neutrophils not available in 19 patients (8 in the Revacept 160 mg group, 7 in the Revacept 80 mg group and 4 in the Placebo group).
[u] Lymphocytes not available in 10 patients (3 in the Revacept 160 mg group, 3 in the Revacept 80 mg group and 4 in the Placebo group).
[v] Eosinophils not available in 13 patients (6 in the Revacept 160 mg group, 3 in the Revacept 80 mg group and 4 in the Placebo group).
[w] Basophils not available in 16 patients (6 in the Revacept 160 mg group, 6 in the Revacept 80 mg group and 4 in the Placebo group).
[x] Monocytes not available in 10 patients (3 in the Revacept 160 mg group, 3 in the Revacept 80 mg group and 4 in the Placebo group).
[y] Activated partial thromboplastin time not available in 8 patients (2 in the Revacept 160 mg group, 3 in the Revacept 80 mg group and 3 in the Placebo group).
[z] Quick not available in 8 patients (2 in the Revacept 160 mg group, 3 in the Revacept 80 mg group and 3 in the Placebo group).
[aa] International normalized ratio not available in 8 patients (2 in the Revacept 160 mg group, 3 in the Revacept 80 mg group and 3 in the Placebo group).

eTable 5. ECG Parameters at 48h

Characteristic	Revacept 160 mg (n = 120)	Revacept 80 mg (n = 119)	Placebo (n = 93)	P value
Pacemaker ECG, No. (%)[a]	7 (5.9)	4 (3.4)	1 (1.1)	0.19
Rhythm, No. (%)[b]				0.34
Sinus rhythm	117 (98.3)	119 (100.0)	92 (100.0)	
Atrial fibrillation	0 (0.0)	1 (0.8)	0 (0.0)	
Other	2 (1.7)	0 (0.0)	0 (0.0)	
Heart rate, median (IQR), beats/min[c]	65.0 (60.0, 71.5)	65.0 (58.2, 75.0)	63.5 (60.0, 71.0)	0.32
PQ interval, median (IQR), ms[d]	176.0 (160.0, 194.0)	170.0 (156.0, 190.0)	173.0 (154.5, 190.0)	0.17
QTc interval, median (IQR), ms[e]	423.0 (404.0, 447.0)	421.0 (400.0, 436.0)	414 (398.5, 435.0)	0.03
Left bundle branch block, No. (%)[f]	1 (0.9)	2 (1.7)	2 (2.2)	0.86

Data are shown for the modified intention-to-treat population.

ECG, electrocardiogram; QTc Interval, corrected QT Interval.

[a] Pacemaker ECG not available in 5 patients (1 in the Revacept 160 mg group, 1 in the Revacept 80 mg group and 3 in the Placebo group).
[b] Rhythm not available 5 patients (1 in the Revacept 160 mg group, 1 in the Revacept 80 mg group and 3 in the Placebo group).
[c] Heart rate not available in 2 patients (1 in the Revacept 160 mg group and 1 in the Placebo group).
[d] PQ Interval not available in 8 patients (3 in the Revacept 160 mg group, 2 in the Revacept 80 mg group and 3 in the Placebo group).
[e]QTc Interval not available in 8 patients (3 in the Revacept 160 mg group, 2 in the Revacept 80 mg group and 3 in the Placebo group).
[f] Left bundle branch block information not available in 8 patients (3 in the Revacept 160 mg group, 2 in the Revacept 80 mg group and 3 in the Placebo group).

eTable 6. Baseline Patient Characteristics in Centers With vs. Without Planned Platelet Function Evaluation (Adenosine Diphosphate-Induced Platelet Aggregation)

Characteristic	Centers with planned PFE (n = 205)	Centers without planned PFE (n = 129)	P value
Age, median (IQR), y	68.6 (61.3, 75.0)	65.9 (60.8, 75.4)	0.33
Female sex, No. (%)	42 (20.5)	39 (30.2)	0.06
Weight, median (IQR), kg	82.0 (73.0, 91.0)	82.0 (71.0, 94.0)	0.84
Race, No. (%)			0.25
Caucasian	204 (99.5)	126 (97.7)	
Black	0 (0.0)	1 (0.8)	
Asian	1 (0.5)	2 (1.6)	
Cardiovascular risk factors, No. (%)			
Diabetes mellitus	50 (24.4)	39 (30.2)	0.29
Insulin therapy	16 (32.0)	15 (38.5)	0.52
Current smoker	41 (20.0)	26 (20.2)	0.96
Arterial hypertension	175 (85.4)	121 (93.8)	0.03
Hypercholesterolemia	188 (91.7)	110 (85.3)	0.10
Medical history, No. (%)			
Myocardial infarction	41 (20.0)	33 (25.6)	0.29
PCI	111 (54.1)	77 (59.7)	0.38
CABG	14 (6.8)	13 (10.1)	0.39
Stroke	3 (1.5)	5 (3.9)	0.27
Peripheral arterial occlusive disease	17 (8.3)	9 (7.0)	0.82
COPD	9 (4.4)	8 (6.2)	0.63
Renal insufficiency	16 (7.8)	15 (11.6)	0.33
Family history of premature CAD, No. (%)	76 (37.1)	65 (51.6)	0.01
High sensitivity cardiac troponin T, median (IQR), ng/L	9.00 (7.00, 11.00)	13.0 (13.00, 13.00)	<0.001
Creatinine, median (IQR), mg/dL	1.00 (0.86, 1.11)	0.90 (0.80, 1.10)	0.02
Body temperature, median (IQR), °C	36.5 (36.4, 36.8)	36.6 (36.4, 36.8)	0.02
Heart rate, median (IQR), beats/min	64.0 (57.0, 70.0)	67.0 (60.0, 74.0)	0.05
Blood pressure, median (IQR), mm Hg			

Systolic	144.0 (130.0, 156.0)	138.0 (124.0, 148.0)	<0.001
Diastolic	80.0 (73.0, 88.0)	78.0 (70,0, 85.0)	0.02
Access site, No. (%)			0.07
femoral	110 (53.7)	54 (41.9)	
radial	94 (45.9)	74 (57.4)	
brachial	1 (0.5)	1 (0.8)	
No. of diseased coronary vessels, No. (%)			0.09
One vessel	40 (19.5)	17 (13.2)	
Two vessels	69 (33.7)	36 (27.9)	
Three vessels	96 (46.8)	76 (58.9)	
Closure device, No. (%)	68 (33.2)	45 (34.9)	0.84

CABG, coronary-artery bypass grafting; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; PCI, percutaneous coronary intervention; PFE, platelet function evaluation.

eTable 7. Angiographic and Interventional Characteristics in Centers With vs. Without Planned Platelet Function Evaluation (Adenosine Diphosphate-Induced Platelet Aggregation)

Characteristic	**Centers with planned PFE (n = 327)**	**Centers without planned PFE (n = 190)**	**P value**
Target vessel, No. (%)			
Left main coronary artery	18 (5.5)	13 (6.8)	
Left anterior descending coronary artery	144 (44.0)	67 (35.3)	
Left circumflex coronary artery	87 (26.6)	44 (23.2)	
Right coronary artery	75 (22.9)	66 (34.7)	
Bypass graft	3 (0.9)	0 (0.0)	
Complex lesion (type B2/C), No. (%)	229 (70.0)	113 (59.5)	0.68
Chronic total occlusion, No. (%)	6 (1.8)	23 (12.1)	>0.99
TIMI flow grade before the intervention, No. (%)			0.38
0	3 (0.9)	14 (7.4)	
1	3 (0.9)	8 (4.2)	
2	13 (4.0)	7 (3.7)	
3	307 (93.9)	161 (84.7)	
Type of intervention, No. (%)			
Drug eluting stent	301 (92.0)	178 (93.7)	0.10
Drug eluting balloon	14 (4.3)	9 (4.7)	0.15
PTCA only	24 (7.3)	8 (4.2)	0.07
Total stented length, median (IQR), mm	23.0 (18.0, 33.0)	24.0 (18.0, 37.8)	0.181
Maximum stent diameter, median (IQR), mm	3.0 (3.0, 3.5)	3.0 (2.8, 3.5)	0.898
Maximum balloon diameter, median (IQR), mm	3.5 (3.0, 3.5)	3.0 (2.5, 3.5)	0.19
Maximum balloon pressure, median (IQR), atm	15.0 (12.0, 18.0)	14.0 (12.0, 16.0)	0.04

TIMI flow grade after the intervention, No. (%)			0.16
0	1 (0.3)	3 (1.6)	
1	2 (0.6)	2 (1.1)	
2	0 (0.0)	0 (0.0)	
3	323 (98.8)	185 (97.4)	

PCI, percutaneous coronary intervention; PFE, platelet function evaluation; PTCA, percutaneous transluminal coronary angioplasty; TIMI, Thrombolysis in Myocardial Infarction.

eTable 8. Evaluation of ADP and Collagen-Induced Platelet Aggregation at 48h

Characteristic	Revacept 160 mg	Revacept 80 mg	Placebo	P value
Patients with planned assessment of collagen-induced platelet aggregation, No.[a]	60	61	47	
Collagen 31 µg/ml, median (IQR), AU x min[b]	11.5 (0.0, 35.2)	25.0 (0.0, 55.0)	17.5 (7.2, 52.0)	0.13
Collagen 93 µg/ml, median (IQR), AU x min[c]	17.0 (0.0, 40.0)	31.0 (6.8, 65.0)	30.5 (13.2, 76.0)	0.03
Collagen 253 µg/ml, median (IQR), AU x min[d]	26.5 (10.5, 62.2)	43.5 (22.8, 99.5)	41.0 (31.2, 101.0)	0.02
Patients with planned assessment of ADP-induced platelet aggregation, No.[e]	73	75	57	
ADP, median (IQR), AU x min[f]	136.0 (99.0, 177.0)	167.0 (109.5, 204.5)	143.0 (108.2, 209.2)	0.11

ADP, Adenosine Diphosphate; AU, Aggregation Unit.

[a] Assessment of collagen-induced platelet aggregation was planned to be done in one participating center.
[b] Not available in 2 patients (1 in the Revacept 80 mg group and 1 in the Placebo group).
[c] Not available in 2 patients (1 in the Revacept 80 mg group and 1 in the Placebo group).
[d] Not available in 4 patients (2 in the Revacept 160 mg group, 1 in the Revacept 80 mg group and 1 in the Placebo group).
[e] Assessment of ADP-induced platelet aggregation was planned to be done in 2 participating centers.
[f] ADP-induced platelet aggregation not available in 1 patient in the Placebo group.

eFigure 1. Kaplan–Meier Survival Curves of Major Adverse Cardiovascular Events (Left Panel) and BARC Type 2 to 5 Bleeding (Right Panel) at 30 Days.



BARC, Bleeding Academic Research Consortium. Major adverse cardiovascular events was the composite of death, myocardial infarction, stroke or urgent coronary revascularisation.

5. eMethods

Inclusion and Exclusion Criteria

Inclusion criteria:

- Signed written informed consent
- Men and women >18 years of age
- Diagnosis: Clinically stable coronary artery disease*
- Angiographic evidence of coronary artery disease
- Indication for PCI

Exclusion criteria:

- WOCBP who are unwilling or unable to use an acceptable method to avoid pregnancy
- for up to 4 weeks after receiving investigational product.
- Women who are pregnant or breastfeeding or are planning pregnancy during course of
- trial
- Women with a positive pregnancy test on enrolment or prior to investigational product
- administration.
- Patients with elevated high sensitivity cardiac troponin T levels at screening
- Patients receiving antithrombotic therapy with Prasugrel or Ticagrelor within 7 days
- prior to randomisation1
- History of hypersensitivity, contraindication or serious adverse reaction to any
- component of the study drug (GPVI-Fc, sucrose, mannitol), acetylsalicylic acid or
- clopidogrel
- History of bleeding diathesis or active bleeding within the last 30 days
- Recent intracerebral hemorrhage or trauma within the last 3 months
- Thrombocytopenia (platelet count <30000/mm3) at screening
- Sustained hypertension (systolic BP >179mmHg or diastolic BP >109mmHg) at

- screening
- Renal failure (estimated glomerular filtration rate< 30ml/min and/or dialysis)
- Severe systemic disease, such as known malignancies or other comorbid conditions
- with life expectancy less than one year that may result in protocol non-compliance
- Unable to provide informed consent (e.g. severe dementia, or psychosis)
- Current severe liver dysfunction (transaminase level >5-fold the upper normal range limit)
- Patients with an indication for anticoagulant therapy
- Participation in any other clinical interventional trial (drug/device) within less than 30 days prior to screening
- Any other contraindication to perform PCI
- Any planned additional PCI or surgery within 30 days after randomisation
- Suspected poor capability to follow instructions and cooperate
- Prisoners or subjects who are involuntarily incarcerated
- Subjects who are compulsorily detained for treatment of either a psychiatric or physical illness (e.g. infectious disease)

*The diagnosis of stable coronary artery disease implies the exclusion of acute coronary syndromes as defined in current guidelines of the European Society of Cardiology (Eur Heart J 2016;37(3):267-315).

Measurement of High Sensitivity Troponin T

Blood samples were collected at baseline before randomization and at least once at 48±12 h after randomization in tubes containing a lithium-heparin anticoagulant. Troponin T was measured by a high-sensitivity assay in a cobas e 411 immunoanalyzer using electrochemiluminescence technology (Roche Diagnostics, Risch-Rotkreuz, Switzerland). The limit of blank for this assay (the concentration below which analyte-free samples are found with 95% probability) is ≤0.003 mg/l. The functional sensitivity (the lowest analyte concentration that can be reproducibly measured with a coefficient of variation ≤10%) is ≤0.013 mg/l. The 99th percentile of healthy persons URL is 0.014 mg/l.